Maky Zanganeh and Dave Gancarz share their take on the result, which at the topline showed that Ivonescimab plus chemo reduced the risk of death by 34% vs the PD-1 Tislelizumab plus chemo, and they are given the opportunity to respond to some of the pushback heard around McCormick Place.

Biotech veteran and Summit Chairman Bob Duggan and Summit's Chief Strategy and Business Officer Dave Gancarz discuss the filing, and discuss trying to stay out front and on top in this emerging new class of medicines.